Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Genelabs gets $1.25M for amendment to DNA amplification technology license
January 27th, 2005
Genelabs Technologies, Inc., (GNLB) announced that it received $1.25 million from Affymetrix, Inc., for an amendment to a nonexclusive license to Genelabs' Linker-Aided DNA Amplification technology, which is known as LADA. Affymetrix had licensed the LADA technology from Genelabs in December 2002. The amendment converts the license to a fully paid up nonexclusive license and eliminates royalties and fees that were payable under the original agreement. The license covers U.S. patent number 6,107,023 entitled "DNA Amplification and Subtraction Techniques" and corresponding international patents. The '023 patent claims a method of amplifying nucleic...
Source: Women's Health Weekly (2005-01-27)
|
